R J Hollis - JoVE Visualize

Showing results (41-50 of 113) with videos related to

Pageof 12

Sort By:

Infection Control and Hospital Epidemiology|January 1, 1993

Restriction endonuclease analysis of plasmid DNA from methicillin-resistant Staphylococcus aureus: clinical application over a three-year periodA Trilla, M D Nettleman, R J Hollis, et al.

Journal of Clinical Microbiology|May 8, 2003

Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazoleM A Pfaller, D J Diekema, L Boyken, et al.

Journal of Clinical Microbiology|May 8, 2003

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationM A Pfaller, S A Messer, L Boyken, et al.

Antimicrobial Agents and Chemotherapy|October 18, 2002

In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methodsM A Pfaller, S A Messer, L Boyken, et al.

Journal of Clinical Microbiology|October 7, 2005

Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance programM A Pfaller, L Boyken, S A Messer, et al.

Journal of Clinical Microbiology|August 6, 2005

In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsM A Pfaller, L Boyken, R J Hollis, et al.

Antimicrobial Agents and Chemotherapy|September 19, 2000

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformansT Yamazumi, M A Pfaller, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|November 1, 1995

Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patientsF Barchiesi, R J Hollis, S A Messer, et al.

Journal of Clinical Microbiology|December 21, 2007

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance programM A Pfaller, S A Messer, L Boyken, et al.

Diagnostic Microbiology and Infectious Disease|October 12, 2004

Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformansM A Pfaller, L Boyken, R J Hollis, et al.

Pageof 12

Showing results (41-50 of 113) with videos related to

Sort By:

Pageof 12

Infection Control and Hospital Epidemiology|January 1, 1993

Restriction endonuclease analysis of plasmid DNA from methicillin-resistant Staphylococcus aureus: clinical application over a three-year periodA Trilla, M D Nettleman, R J Hollis, et al.

Journal of Clinical Microbiology|May 8, 2003

Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazoleM A Pfaller, D J Diekema, L Boyken, et al.

Journal of Clinical Microbiology|May 8, 2003

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationM A Pfaller, S A Messer, L Boyken, et al.

Antimicrobial Agents and Chemotherapy|October 18, 2002

In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methodsM A Pfaller, S A Messer, L Boyken, et al.

Journal of Clinical Microbiology|October 7, 2005

Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance programM A Pfaller, L Boyken, S A Messer, et al.

Journal of Clinical Microbiology|August 6, 2005

In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsM A Pfaller, L Boyken, R J Hollis, et al.

Antimicrobial Agents and Chemotherapy|September 19, 2000

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformansT Yamazumi, M A Pfaller, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|November 1, 1995

Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patientsF Barchiesi, R J Hollis, S A Messer, et al.

Journal of Clinical Microbiology|December 21, 2007

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance programM A Pfaller, S A Messer, L Boyken, et al.

Diagnostic Microbiology and Infectious Disease|October 12, 2004

Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformansM A Pfaller, L Boyken, R J Hollis, et al.

Pageof 12